IGF-I Promotes the Development of Epilepsy through Activation of Akt-mTOR Cascade

Lauren Boller

Follow this and additional works at: http://preserve.lehigh.edu/undergrad-scholarship-freed-posters

Recommended Citation
Boller, Lauren, "IGF-I Promotes the Development of Epilepsy through Activation of Akt-mTOR Cascade" (2016). David and Lorraine Freed Undergraduate Research Symposium Posters. 1.
http://preserve.lehigh.edu/undergrad-scholarship-freed-posters/1
IGF-I Promotes the Development of Epilepsy through Activation of Akt-mTOR Cascade

Lauren Boller1, Katherine Walters2, Corrin Pimentel1, Yu Song1, Yevgeny Berdichevsky1,3

1Bioengineering Program, 2IDEAS Program, 3Department of Electrical and Computer Engineering
Lehigh University, Bethlehem PA

Significance

• According to the Center for Disease Control and Prevention, epilepsy affects 65 million people worldwide.
• 5% of all cases of epilepsy are caused by traumatic brain injury (TBI)
• Epileptogenesis occurs during the latent period between the time of injury and the onset of seizures
• Insulin-like Growth Factor-I (IGF-I) is found in the cerebrospinal fluid of healthy individuals.
  • Following head injury, IGF-I levels are elevated in the brain tissue
  • Objective: To determine the role of IGF-I in epileptogenesis and find potential targets for antiepileptic drugs

Methods

• In vivo: Acquired nine mice brain samples with three different treatments
  • Control Brains: Normal brain dissection
  • Sham Brains: Drilled opening into the skull
  • CCI Brains: Drilled opening into the skull and delivered controlled impact to intact dura
  • Brain samples dissected from four locations: Ipsilateral Cortex (IC), Contralateral Cortex (CC), Ipsilateral Hippocampus (IH) Contralateral Hippocampus (CH)
• In vitro: Organotypic hippocampal cultures maintained in the presence of IGF-I or vehicle, and harvested at various time points for analysis

Figure 1: Representative time course of epileptogenesis in an organotypic hippocampal culture. Colors correspond to the frequency of paroxysmal event occurrence in 10 s bins, with examples shown on the right. Deep blue, multiunit activity (top trace); light blue or yellow (middle trace); red, electrographic seizures (ical events, bottom trace).

Figure 2: Diagram indicating the location of drilling and Controlled Cortical Impact (CCI)

Results

• Tissues lyed in buffer containing protease and phosphatase inhibitors. BCA analysis used to determine total concentration of protein in solution. Western blotting carried out and exposed films analyzed using Fiji (NIH) software.
• Ratio of Phosphorylated Protein = Phosphorylated Protein
  Total Protein

Figure 3: Phosphorylation of IGF-1R, Akt, MAPK, and S6 in CCI brains. A) Ratio of phosphorylated versus total protein band intensity in Cortex. B) Ratio of phosphorylated versus total protein band intensity in Hippocampus. N=3. *p< 0.05, **p<0.01

Figure 4: Prolonged, late IGF-1 activates Akt-mTOR, but not MAPK signaling. A) Representative Western Blots of phosphorylated and total Akt, MAPK, and S6 on DIV 6. IGF-1 treatment indicated with (+), vehicle treatment indicated with (-). B) Quantification of band densities. Ratios for vehicle-treated cultures were used for normalization. N=6. C) Comparison of total (all) protein detected in single culture lyses reveals that IGF-1 treated cultures have higher protein content than vehicle treated cultures. Data are represented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.

Conclusion

• IGF-I is involved in post-traumatic signaling within the brain
• IGF-I is neuroprotective immediately after injury, but pro-epileptogenic longterm
• Both models suggest the pro-epileptogenic effects of IGF-I are mediated by Akt-mTOR signaling
• Modulation of the IGF-I-Akt-mTOR signaling may form a basis for new antiepileptic treatments

Acknowledgements

David and Lorraine Freed Undergraduate Research Symposium, Lehigh University

We wish to thank Dr. Josephine Lok at Massachusetts General Hospital for providing the brain tissue for analysis

This research was supported by Citizens United for Research in Epilepsy (CURE)